氯沙坦钾联合益肾健脾化湿颗粒治疗慢性肾小球肾炎临床疗效及安全性评价.docVIP

氯沙坦钾联合益肾健脾化湿颗粒治疗慢性肾小球肾炎临床疗效及安全性评价 　　[摘要] 目的 探讨在慢性肾小球肾炎治疗的过程中，使用氯沙坦钾联合益肾健脾化湿颗粒治疗的疗效及其安全性。 方法 针对30例慢性肾小球肾炎患者采用氯沙坦钾治疗，并设为对照组，针对另外30例患者在对照组基础上联合益肾健脾化湿颗粒治疗，并设为观察组，两组患者均为我院2013年2月～2014年1月期间门诊病例。 结果 两组患者24小时尿蛋白、血肌酐、血钾、白细胞介素-13、舒张压和收缩压等在无差异的基础上分组治疗。治疗后观察组患者效果明显更佳；比较两组患者的治疗有效率发现，观察组患者为83.33%明显较高，对照组为63.33%，且组间比较均为P0.05则说明差异明显。不良反应比较无明显差异，但是观察组患者13.33%明显较低，对照组为23.33%。 结论 氯沙坦钾联合益肾健脾化湿颗粒治疗慢性肾小球肾炎的临床疗效及安全性评价分析发现，能够改善患者临床各项指标，提高患者的临床治疗效果，同时不会对患者产生不良反应，因此值得临床借鉴。 　　[关键词] 氯沙坦钾；益肾健脾化湿颗粒；慢性肾小球肾炎；安全性 　　[中图分类号] R692.31 [文献标识码] A [文章编号] 2095-0616（2017）08-61-04 　　[Abstract] Objective To investigate the clinical efficacy and safety of losartan potassium combined with Yishen Jianpi Huashi granules in the treatment of chronic glomerulonephritis. Methods 30 cases of control group were treated with Losartan potassium， and 30 cases of observation group were treated with losartan potassium combined with Yishen Jianpi Huashi granules. All cases were outpatient cases in our hospital from Feb 2013 to Jan 2014. Results 24 hours urine protein， serum creatinine， serum potassium， interleukin -13， diastolic blood pressure and systolic blood pressure of two groups before treatment showed no significant difference. After treatment， clinical efficacy of observation group was better； A comparison of the treatment effectiveness betwee two groups showed that， the observation group was 83.33%， and the control group was 63.33%， which shwoed significant difference （P0.05）. Adverse reaction of observation group was 13.33%， and the control group was 23.33%， which showes no significant difference. Conclusion Losartan potassium combined with Yishen Jianpi Huashi granules for Chronic glomerulonephritis can improve the clinical indicators of patients， improve the clinical treatment of patients， without adverse reaction， worthy of clinical promotion. 　　[Key words] Losartan potassium； Yishen Jianpi Huashi granules； Chronic glomerulonephritis； Safety 　　慢性?I小球肾炎是临床中常见的一类疾病，病情发生多是因为患者的局部或肾部出现弥散性炎症，该病的病程往往较为缓慢，同时患者的病